TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Liver Transplantation for Cholangiocarcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
The surgical protocol will initially be offered to liver transplant candidates with de novo hilar CCA or CCA arising in the setting of PSC. Diagnosis of CCA will be established by intraluminal brush cytology, intraluminal biopsy, or a carcinoma antigen (CA) 19.9 level greater than 100 ng / mL in the setting of a radiographic malignant stricture.~Biliary aneuploidy demonstrated with DIA and FISH will be considered equivalent to cytology.~All patients with CCA will be evaluated by the liver transplant team which includes experienced hepatobiliary and liver transplant surgeons. Patients will be presented at the weekly liver transplant selection conference to assess their candidacy as well as the weekly GI Multidisciplinary Tumor Conference at the Huntsman Cancer Institute. Clinical staging prior to neoadjuvant therapy will include chest and abdominal computed tomography, liver ultrasound, and bone scan. Patients will also undergo endoscopic ultrasound with fine needle aspiration of suspicious lymph nodes.~All patients will undergo staging laparoscopy to rule out the presence of peritoneal disease followed by staging laparotomy.~Patients with N1 disease (metastasis to lymph nodes within hepatoduodenal ligament) will remain eligible for the protocol.~Tumor size will not be included in the exclusion criteria. Patients with evidence of disease progression beyond study criteria will not be eligible to continue on to liver transplantation.~\*\* Patients with metastatic disease are not eligible for this trial \*\*~Exclusion criteria will include:~* previous chemotherapy or radiotherapy,~* uncontrolled infection,~* a previous malignance other than non-melanoma skin cancer or in situ cervical cancer within the last five years,~* medical conditions precluding transplantation,~* metastatic disease (including N2 disease), and~* patients with hilar tumors extending below the cystic duct.~Patients with extrahepatic metastases, local spread of disease to adjacent organs, and N2 nodal disease (metastasis to peripancreatic, periduodenal, periportal, celiac, superior mesenteric, and / or posterior pancreaticoduodenal nodes) will be excluded as will patients with extension of tumor into the main portal vein.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- All participants (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Intranasal Treatment of HIV-associated Neurocognitive Disorders

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Documented HIV-1 infection~* Maintained on stable ART for ≥6 months (defined as undetectable viral load)~* HAND-MND or -ANI diagnosis with evidence of clinical onset or progression within the prior 2 years, based on established criteria~* Currently followed at the Southern Alberta Clinic (SAC; Calgary, AB, Canada)~Exclusion Criteria:~* HAND with a) changed dose of any medication for HIV-1 infection with a corresponding increase in viral load (e.g., ART), or b) secondary therapies for HAND (e.g., memantine, amphetamines).~* Advanced liver, renal or lung disease, cancer or diabetes requiring insulin~* Secondary diagnosis of neurocognitive impairment or other major neuropsychiatric illness such as epilepsy, Alzheimer's or Parkinson's diseases, major depression (PHQ-9 score \>10), or schizophrenia~* Central nervous system lesion (diagnosed by neuroimaging) that may impair cognition~* Previous allergic reaction to insulin or any of the carrier components.~* Education \< 9 years or inability to read and write English fluently~* Uncontrolled HIV-1 or hepatitis C co-infection~* Inability to perform NP or questionnaire measures, functional illiteracy~* Past or current substance abuse that could interfere with the study assessments as determined by the PI~* Marijuana use on the day of NP testing~* Uncontrolled cardiovascular disease (hypertension, coronary or peripheral artery disease)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IN insulin 40 IU (Type: ACTIVE_COMPARATOR): Drug: IN insulin Dosage form: intranasal Dose: 40 IU Frequency: bid Duration: 16 weeks
- IN Sterile Saline (Type: PLACEBO_COMPARATOR): Drug: Sterile Saline Dosage form: intranasal Frequency: bid Duration: 16 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Spine Rehabilitation Using Spine Flexion / Extension Full Active Range of Motion for Patients With Chronic Low Back Pain

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Medical prescription for chronic low back pain rehabilitation~* Evolution of low back pain for at least 3 months~* No treatment or rehabilitation for low back pain performed within 12 months before enrollment~* Written informed consent given~Exclusion Criteria:~* Spinal fracture or previous spinal surgery~* Cognitive impairments that prevent from understanding the rehabilitation exercises~* Patient with insufficient understanding or expression in French~* Non-mechanical pain : gradually worsening pain, present at rest and especially at night~* Neurological symptom : deficit in the control of bladder and anal sphincters, motor weakness of lower limbs, Cauda equina syndrome~* Pubis paresthesia (or perineum)~* Severe trauma (such as fall from height, traffic accident)~* Unexplained weight loss~* History of cancer~* Drug use or long-term use of corticosteroid~* Spinal deformity~* Altered general condition~* Patient with signs of neurological impairment : positive Lasegue test (Straight Leg Raise Test) or positive Slump test, or DN4 questionnaire greater than or equal to 4~* Patient suffering from a central or peripheral neurological pathology~* Patient taking a level II (weak opiates) or III (morphine and related substances) analgesic treatment~* Patient under guardianship, curatorship or legal protection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients with chronic low back pain (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Acetyl-L-carnitine on Chronic Pancreatitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Only patients with chronic pancreatitis are included.~Exclusion Criteria:~* Patients with pancreatic pseudocysts, abscesses, pseudoaneurysms, pancreatitic fistulas, pancreatic adenocarcinoma,~* Females that are pregnant or lactating~* Children are excluded.~* Patients suffering from seizure or thyroid disorders are also excluded due to possible exaggeration of their symptoms from taking ALC according to manufacturer.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): Acetyl-L-carnitine 1000mg 2X per day for 3 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Antineoplaston Therapy in Treating Patients With Primary Liver Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed primary liver cancer that is unlikely to respond to existing therapy and for which no curative therapy exists~* Measurable disease by CT scan or MRI~* Tumor must be at least 2 cm~PATIENT CHARACTERISTICS:~Age:~* 14 and over~Performance status:~* Karnofsky 60-100%~Life expectancy:~* At least 2 months~Hematopoietic:~* WBC at least 2,000/mm3~* Platelet count at least 50,000/mm3~Hepatic:~* Bilirubin less than 3 mg/dL~* SGOT/SGPT no greater than 10 times upper limit of normal~* No hepatic failure~Renal:~* Creatinine no greater than 2.5 mg/dL~* No history of renal conditions that contraindicate high doses of sodium~Cardiovascular:~* No uncontrolled hypertension~* No known chronic heart failure~* No history of congestive heart failure~* No history of other cardiovascular conditions that contraindicate high doses of sodium~Pulmonary:~* No serious lung disease (e.g., chronic obstructive pulmonary disease)~Other:~* Not pregnant or nursing~* Fertile patients must use effective contraception for 4 weeks before study, during study, and for 4 weeks after study~* No serious medical or psychiatric disease~* No active infection~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* At least 4 weeks since prior immunotherapy and recovered~* No concurrent immunomodulating agents~Chemotherapy:~* At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered~* No concurrent antineoplastic agents~Endocrine therapy:~* Concurrent steroids allowed~Radiotherapy:~* At least 8 weeks since prior radiotherapy and recovered~Surgery:~* Recovered from prior surgery~Other:~* No prior antineoplaston therapy~* Prior cytodifferentiating agents allowed

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Antineoplaston Therapy (Type: EXPERIMENTAL): Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness Study of Santyl Ointment to Treat Pressure Ulcers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 to 85 year-old competent adults in inpatient setting (no prisoners, mentally ill, or children)~* Pressure ulcers to pelvis/abdomen/trunk and or upper extremities which have been refractory to prior treatment interventions and contain less than or equal to 25% necrotic tissue in wound bed (as percentage of total surface area)~Exclusion Criteria:~* Lower extremity/foot wounds related to arterial insufficiency, incarcerated individuals, patients with untreated osteomyelitis, uncorrected coagulopathy, malignancy, sensitivity to collagenase, wounds with evidence of clinical infection (via swab culture or punch biopsy)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- Negative pressure wound therapy (Type: ACTIVE_COMPARATOR): NPWT changed TIW
- NPWT plus Collagenase Ointment (Type: EXPERIMENTAL): Collagenase applied TIW with NPWT

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Lateral Ankle Sprain Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 \& Over~* Lateral Ankle Sprain (Grade II or III) presenting within 48 hours of initial injury without prior treatment~Exclusion Criteria:~* Patients less than 18 years old~* Those not able to give consent~* Women who are pregnant or are expecting to become pregnant~* \> 48 hrs from injury at time of presentation~* Prior treatment for injury~* Fracture at time of current ankle injury or previous ankle fracture~* Deltoid ligament injuries~* Other orthopaedic injuries at time of presentation~* Intoxication~* Workman's Compensation injury~* Mental Illness~* Dementia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Air Cast Stirrup Brace (Type: ACTIVE_COMPARATOR): 50 patients will be randomly assigned to receive the Air Cast Stirrup Brace.
- High Tide Fracture Boot (Type: ACTIVE_COMPARATOR): 50 patients will be randomly assigned to the High Tide Fracture Boot.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Endoscopic Sinus Surgery for Chronic Sinusitis on Asthma Control

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Inclusion criteria: General~  1. 18 years of age or older~ 2. Women need one of the following: negative pregnancy test or suitable birth control or post-menopausal status~ 3. Informed consent and ability to comply with study procedures~ 4. Patients must meet inclusion criteria for both asthma and sinus disease.~Inclusion criteria: Asthma~In order to qualify for the 6 week run-in, patients must have poorly controlled asthma as defined by the following criteria:~1. Diagnosis of asthma confirmed either by demonstrating a positive methacholine challenge test (defined as a decrease in FEV1 by at least 20%, following administration of 8mg or less of inhaled methacholine) or a positive bronchodilator response (defined as a change from base line of \>12% and at least 200ml in either FEV1 or FVC, following administration of a short-acting, inhaled bronchodilator).~2. Either:~   * Asthma Control Questionnaire score \> 1.5 or~  * Use of inhaled rescue ß-agonist \>/= 16 puffs per week (excluding use as a pre-medication for exercise; 1 nebulizer treatment = 2 puffs of inhaler) at any time during the past month or~  * \>1 hospitalization or unscheduled MD visit in the past 6 months for asthma symptoms or~  * \>1 course of oral steroid use in past 6 months or~  * \> 2 weeks of systemic steroids in last 6 months.~Exclusion Criteria:~1. Current smokers or those with at least a 10 pack-year smoking history~2. Presence of any concurrent diseases that, in the investigator's opinion, would interfere with participation in the study or that might put the participant at risk

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Medical therapy (Type: PLACEBO_COMPARATOR): Patients undergo surgery 6 months after randomization
- Surgery (Type: EXPERIMENTAL): Patients undergo surgery at time of randomization

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Imaging of Intravenous (IV) Combidex to Brain, Intra-cerebral Tumors and in Central Nervous System (CNS) Inflammation

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* Brain tumor or CNS inflammatory lesion including stroke or MS~* 5 yrs old or older~* Able to undergo MRI without general anesthesia~* Agree to be followed for 1 month following infusion of Combidex~* Sign a written informed consent~* If female and of child-bearing potential, be postmenopausal, sterile, or be on birth control for 1 month prior to study~* Must have a pre-treatment MRI within 28 days before study~Exclusion Criteria:~* Clinically significant signs of uncal herniation~* Allergy to study drug, Combidex~* Hepatic insufficiency~* Stage IV or V renal insufficiency~* If female, pregnant or lactating~* Require anesthesia for MRI scanning~* Hemachromatosis

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Adults with brain tumor to receive Combidex infusion only
- 2 (Type: ACTIVE_COMPARATOR): Adults with brain tumors to receive Combidex infusion and neurosurgery
- 3 (Type: OTHER): Adults with brain tumors to receive neurosurgery only (NO Combidex)
- 4 (Type: ACTIVE_COMPARATOR): Children with brain tumors to receive Combidex only
- 5 (Type: ACTIVE_COMPARATOR): Children with brain tumors to receive Combidex and neurosurgery
- 6 (Type: OTHER): Children with brain tumors to receive neurosurgery only, NO Combidex
- 7 (Type: ACTIVE_COMPARATOR): Adults with Inflammatory lesions (stroke or MS) to receive Combidex only

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Continuous Thoracic Paravertebral Analgesia for Video-assisted Thoracoscopic Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients scheduled for an elective or emergency VATS surgery (lobectomy or bilobectomy)~* Patients eligible for fast-track surgery~* American Society of Anesthesiologists (ASA) physical status from 1 to 3~Exclusion Criteria:~* Contraindication to paravertebral nerve blockade~* Severe hepatic insufficiency~* Renal insufficiency~* Known allergy to local anesthetics, morphine or hydromorphone~* Contraindication to acetaminophen or non-steroidal anti-inflammatory drugs (NSAID)~* Inability to understand a verbal numeric pain scale despite previous instruction~* Inability to understand the instructions and precautions related to the use of a portable infusion pump or absence of a resource person or natural caregiver at home~* Preexisting pain at the site where the surgical incision will be made~* Current use of opioids, anticonvulsants or tricyclic antidepressants~* Recent history of drug or opioid abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Paravertebral analgesia (Type: EXPERIMENTAL): A paravertebral nerve block will be performed under ultrasound guidance by the anaesthesiologist prior to the induction of general anesthesia. A catheter will be inserted and a continuous infusion of bupivacaine will be administered.
- Intercostal analgesia (Type: ACTIVE_COMPARATOR): An intercostal nerve block using a single dose of bupivacaine will be performed by the surgeon at the end of surgery before skin closure.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: An Assessment of an Attenuated Live Listeria Vaccine in CIN 2+

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed CIN 2/3 that requires surgical intervention~Exclusion Criteria:~* Previous history of listeriosis~* Steroid use~* Antibiotic use~* Negative anergy panel~* HIV positive~* Pregnant or actively trying during the treatment period~* Intercurrent disease

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Low Dose (Type: EXPERIMENTAL): 5x10\^7 cfu x 3 intravenous infusions at 28 day intervals. All infusions will be preceded by prophylactic NSAID and antihistamine, and followed 3d later with antibiotic.
- Middle Dose (Type: EXPERIMENTAL): 3.3x10\^8 cfu x 3 intravenous infusions at 28 day intervals. All infusions will be preceded by prophylactic NSAID and antihistamine, and followed 3d later with antibiotic.
- High Dose (Type: EXPERIMENTAL): 1x10\^9 cfu x 3 intravenous infusions at 28 day intervals. All infusions will be preceded by prophylactic NSAID and antihistamine, and followed 3d later with antibiotic.
- Placebo (Type: PLACEBO_COMPARATOR): normal saline x 3 intravenous infusions at 28 day intervals. All infusions will be preceded by prophylactic NSAID and antihistamine, and followed 3d later with antibiotic.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Dual Energy Computerized Tomography (DE-CT) in Patients With Crohn's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age over 18 years,~* known Crohn's disease (at least 3 moths prior)~* obstructive symptoms~* scheduled for abdominal CT for evaluation of symptoms (regardless of participation in the study)~Exclusion Criteria:~* Pregnancy~* Contraindication to perform CT with IV contrast media

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy